Brca1 heterozygous mice have shortened life span and are prone to ovarian tumorigenesis with haploinsufficiency upon ionizing irradiation

Y. M. Jeng, S. Cai-Ng, A. Li, S. Furuta, Helen K Chew, P. L. Chen, E. Y H Lee, W. H. Lee

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

BRCA1 mutation carriers have an 85% lifetime risk of breast cancer and 60% for ovarian cancer. BRCA1 facilitates DNA double-strand break repair, and dysfunction of BRCA1 leads to hypersensitivity to DNA damaging agents and consequently genomic instability of cells. In this communication, we have examined the tumor incidence and survival of Brca1 heterozygous female mice. Brca1 heterozygotes appear to have a shortened life span with 70% tumor incidence. Lymphoma, but not ovarian and mammary gland tumors, occurs commonly in these mice. After a whole-body exposure to ionizing radiation, Brca1 heterozygous mice have a 3-5-fold higher incidence specific to ovarian tumors, but not lymphoma, when compared with the Brca1+/+ mice. All the tumors from heterozygous mice examined retain the wild-type allele and the cancer cells express Brca1 protein, precluding the chromosomal mechanism for loss of heterozygosity of Brca1 locus. Although the manifestation of BRCA1 haploinsufficiency may be different between human and mouse, this study suggests that women carrying Brca1 mutations may be more prone to ovarian tumor formation after IR exposure than nonmutation carriers.

Original languageEnglish (US)
Pages (from-to)6160-6166
Number of pages7
JournalOncogene
Volume26
Issue number42
DOIs
StatePublished - Sep 13 2007

Fingerprint

Haploinsufficiency
Carcinogenesis
Neoplasms
Lymphoma
Incidence
Breast Neoplasms
Mutation
Double-Stranded DNA Breaks
Genomic Instability
Loss of Heterozygosity
Human Mammary Glands
Heterozygote
Ionizing Radiation
Ovarian Neoplasms
Hypersensitivity
Alleles
Survival
DNA
Proteins

Keywords

  • BRCA1
  • Haploinsufficiency
  • Heterozygous mutant
  • Ionizing radiation
  • Ovarian tumor

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Brca1 heterozygous mice have shortened life span and are prone to ovarian tumorigenesis with haploinsufficiency upon ionizing irradiation. / Jeng, Y. M.; Cai-Ng, S.; Li, A.; Furuta, S.; Chew, Helen K; Chen, P. L.; Lee, E. Y H; Lee, W. H.

In: Oncogene, Vol. 26, No. 42, 13.09.2007, p. 6160-6166.

Research output: Contribution to journalArticle

Jeng, Y. M. ; Cai-Ng, S. ; Li, A. ; Furuta, S. ; Chew, Helen K ; Chen, P. L. ; Lee, E. Y H ; Lee, W. H. / Brca1 heterozygous mice have shortened life span and are prone to ovarian tumorigenesis with haploinsufficiency upon ionizing irradiation. In: Oncogene. 2007 ; Vol. 26, No. 42. pp. 6160-6166.
@article{ec9644b1c2a1403fa5a4d0b29694368e,
title = "Brca1 heterozygous mice have shortened life span and are prone to ovarian tumorigenesis with haploinsufficiency upon ionizing irradiation",
abstract = "BRCA1 mutation carriers have an 85{\%} lifetime risk of breast cancer and 60{\%} for ovarian cancer. BRCA1 facilitates DNA double-strand break repair, and dysfunction of BRCA1 leads to hypersensitivity to DNA damaging agents and consequently genomic instability of cells. In this communication, we have examined the tumor incidence and survival of Brca1 heterozygous female mice. Brca1 heterozygotes appear to have a shortened life span with 70{\%} tumor incidence. Lymphoma, but not ovarian and mammary gland tumors, occurs commonly in these mice. After a whole-body exposure to ionizing radiation, Brca1 heterozygous mice have a 3-5-fold higher incidence specific to ovarian tumors, but not lymphoma, when compared with the Brca1+/+ mice. All the tumors from heterozygous mice examined retain the wild-type allele and the cancer cells express Brca1 protein, precluding the chromosomal mechanism for loss of heterozygosity of Brca1 locus. Although the manifestation of BRCA1 haploinsufficiency may be different between human and mouse, this study suggests that women carrying Brca1 mutations may be more prone to ovarian tumor formation after IR exposure than nonmutation carriers.",
keywords = "BRCA1, Haploinsufficiency, Heterozygous mutant, Ionizing radiation, Ovarian tumor",
author = "Jeng, {Y. M.} and S. Cai-Ng and A. Li and S. Furuta and Chew, {Helen K} and Chen, {P. L.} and Lee, {E. Y H} and Lee, {W. H.}",
year = "2007",
month = "9",
day = "13",
doi = "10.1038/sj.onc.1210451",
language = "English (US)",
volume = "26",
pages = "6160--6166",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "42",

}

TY - JOUR

T1 - Brca1 heterozygous mice have shortened life span and are prone to ovarian tumorigenesis with haploinsufficiency upon ionizing irradiation

AU - Jeng, Y. M.

AU - Cai-Ng, S.

AU - Li, A.

AU - Furuta, S.

AU - Chew, Helen K

AU - Chen, P. L.

AU - Lee, E. Y H

AU - Lee, W. H.

PY - 2007/9/13

Y1 - 2007/9/13

N2 - BRCA1 mutation carriers have an 85% lifetime risk of breast cancer and 60% for ovarian cancer. BRCA1 facilitates DNA double-strand break repair, and dysfunction of BRCA1 leads to hypersensitivity to DNA damaging agents and consequently genomic instability of cells. In this communication, we have examined the tumor incidence and survival of Brca1 heterozygous female mice. Brca1 heterozygotes appear to have a shortened life span with 70% tumor incidence. Lymphoma, but not ovarian and mammary gland tumors, occurs commonly in these mice. After a whole-body exposure to ionizing radiation, Brca1 heterozygous mice have a 3-5-fold higher incidence specific to ovarian tumors, but not lymphoma, when compared with the Brca1+/+ mice. All the tumors from heterozygous mice examined retain the wild-type allele and the cancer cells express Brca1 protein, precluding the chromosomal mechanism for loss of heterozygosity of Brca1 locus. Although the manifestation of BRCA1 haploinsufficiency may be different between human and mouse, this study suggests that women carrying Brca1 mutations may be more prone to ovarian tumor formation after IR exposure than nonmutation carriers.

AB - BRCA1 mutation carriers have an 85% lifetime risk of breast cancer and 60% for ovarian cancer. BRCA1 facilitates DNA double-strand break repair, and dysfunction of BRCA1 leads to hypersensitivity to DNA damaging agents and consequently genomic instability of cells. In this communication, we have examined the tumor incidence and survival of Brca1 heterozygous female mice. Brca1 heterozygotes appear to have a shortened life span with 70% tumor incidence. Lymphoma, but not ovarian and mammary gland tumors, occurs commonly in these mice. After a whole-body exposure to ionizing radiation, Brca1 heterozygous mice have a 3-5-fold higher incidence specific to ovarian tumors, but not lymphoma, when compared with the Brca1+/+ mice. All the tumors from heterozygous mice examined retain the wild-type allele and the cancer cells express Brca1 protein, precluding the chromosomal mechanism for loss of heterozygosity of Brca1 locus. Although the manifestation of BRCA1 haploinsufficiency may be different between human and mouse, this study suggests that women carrying Brca1 mutations may be more prone to ovarian tumor formation after IR exposure than nonmutation carriers.

KW - BRCA1

KW - Haploinsufficiency

KW - Heterozygous mutant

KW - Ionizing radiation

KW - Ovarian tumor

UR - http://www.scopus.com/inward/record.url?scp=34347354474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347354474&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1210451

DO - 10.1038/sj.onc.1210451

M3 - Article

VL - 26

SP - 6160

EP - 6166

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 42

ER -